Patent helps the distinctive potential of Biofidelity’s expertise to ship ultra-sensitive detection of guideline-recommended tumor markers
CAMBRIDGE, United Kingdom, April 07, 2021 (GLOBE NEWSWIRE) — Biofidelity Ltd, the most cancers diagnostics firm, at the moment introduced that it has been granted a key patent within the US defending its underlying expertise. The grant of US patent US20200354786 has confirmed the novelty and inventiveness of its expertise, which is designed to interrupt down boundaries to raised screening, monitoring and remedy of most cancers by way of ultra-sensitive detection of the important thing tumor markers advisable in remedy pointers.
It combines quick, easy-to-interpret outcomes with affordability, enabling oncologists to make exact selections earlier, monitor resistance and monitor illness recurrence. Biofidelity expects to launch its first product, Identi-Lung, for the detection of non-small cell lung most cancers, later this 12 months.
Dr. Barnaby Balmforth, Chief Govt Officer of Biofidelity, commented: “The grant of this key patent within the US is one other vital step ahead in our aim of reworking prognosis to verify each most cancers affected person receives the appropriate drug on the proper time. We’re working laborious to construct a complete portfolio of IP defending our expertise, purposes and merchandise to allow any lab to supply prime quality precision most cancers diagnostics.”
Biofidelity, a personal firm based in 2019 in Cambridge, UK, is revolutionizing entry to best-in-class most cancers diagnostics, breaking down the boundaries to raised screening, monitoring and remedy for all most cancers sufferers. Its disruptive diagnostic expertise platform will present oncologists with clinically actionable knowledge primarily based on ultra-sensitive detection of markers advisable in most cancers remedy pointers, enabling them to prescribe the appropriate most cancers drug on the proper time. It’s designed to mix quick and easy-to-interpret outcomes with affordability and easy adoption on present laboratory infrastructure, enabling many extra laboratories to supply prime quality most cancers diagnostics. Biofidelity is initially specializing in prognosis of non-small cell lung and colorectal most cancers, with potential in a broad vary of cancers and medium- to long-term purposes within the detection of resistance to remedy and illness recurrence.
For extra info, please go to www.biofidelity.com
For enquiries, please contact:
Dr Barnaby Balmforth, CEO
T: +44 1223 358652
E: [email protected]
|Mo PR Advisory
Mo Noonan/ Jonathan Birt
Tel: +44 (0) 7876 444977 / (0) 7860 361746